Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Mesoblast LimitedNASDAQ: MESO

Other Income / Expenses · Q4 FY2026 · quarter ended Jun 2026

Other income / expenses turns negative

Q4 FY2026 other income / expenses was -$54.96M, compared with $7.32M a year earlier. Trailing-twelve-month other income / expenses was -$5.64M.

Context

  • Other income / expenses amounted to 4.7% of revenue in FY2026, down 224.2 pp from a year earlier.
  • Other income / expenses grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$54.96M or moves back toward the trailing-twelve-month quarterly average of -$1.41M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$54.96M-561.6% QoQ
Last fiscal yearJun 2026
-$5.64M+85.7% YoY
LTMJun 2026
-$5.64M-169.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-850.6%——
1 year+85.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2026
(5.64M) USD
Year-over-year change
+85.7%

Other Income / Expenses vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 other income / expenses of -$5.64M is the 4th highest of the 6 companies compared; the peer median is -$1.9M.
  • Its year-over-year change of -169.1% is the 5th highest of 6, against a peer median of -55.7%.
  • Other income / expenses amounts to 4.7% of revenue for MESO, versus a peer median of 132.6%.
MESO Competitors Peer median
Other Income / Expenses for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$9.52M -61.3%-24.7%150.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$5.34M +140.8%+66.0%—
LEGNLegend Biotech CorporationLTM Sep 2026-$1.9M +94.1%—0.1%
MESOMesoblast LimitedLTM Jun 2026-$5.64M -169.1%—4.7%
CELUCelularity Inc.LTM Dec 2025-$30.41M -55.7%—114.5%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$31.59M -712.7%—213.7%
Peer median (excluding MESO) -$1.9M-55.7%+20.6%132.6%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.